JTE 013
目录号 : GC12947
JTE 013是一种强效、口服可用的靶向S1P2拮抗剂，对大鼠S1P2的IC50值为22±9nM。
Cas No.:383150-41-2
Sample solution is provided at 25 µL, 10mM.
JTE 013 is a potent, orally available, and targeted S1P2 antagonist, with an IC50 value of 22±9nM for rat S1P2 [1]. JTE 013 inhibited the production of inflammatory cytokines and S1P, reduced monocyte chemotaxis, and inhibited RANKL-induced osteoclast precursor adhesion and fusion by targeting S1PR2[2]. JTE 013 has been widely used to regulate smooth muscle contraction and attenuate hypoxia-induced pulmonary hypertension in rodents[3].
In vitro, JTE 013 treatment for 72 hours significantly inhibited GH3 cell viability with an IC50 value of 41.17μM [4]. JTE 013 treatment for 3 hours markedly suppressed ceramide production in MV411 cells with an IC50 value of 16.6 ± 2.8µM[5]. Treatment with 10µM JTE 013 for 4h restored the lipopolysaccharide (LPS)-induced decrease in cell viability of human pulmonary microvascular endothelial cells (HPMECs), reduced inflammation levels, and abolished the inhibitory effect of LPS on junction protein levels in HPMECs[6].
In vivo, JTE 013 treatment via intraperitoneal injection (8mg/kg) once every other day for 5 days can reduce bleomycin-induced pulmonary fibrosis and inhibit the expression of RHOA/YAP pathway proteins in lung tissues of mice[7]. Treatment with JTE 013 at a dose of 2mg/kg via intraperitoneal injection every other day for 3 days in mice with bile duct ligation significantly reduced serum total bile acid levels and alleviated cholestatic liver injury[8].
References:
[1] Li M H, Swenson R, Harel M, et al. Antitumor activity of a novel sphingosine-1-phosphate 2 antagonist, AB1, in neuroblastoma[J]. The Journal of Pharmacology and Experimental Therapeutics, 2015, 354(3): 261-268.
[2] Yu H. Targeting S1PRs as a therapeutic strategy for inflammatory bone loss diseases—beyond regulating S1P signaling[J]. International Journal of Molecular Sciences, 2021, 22(9): 4411.
[3] Blankenbach K V, Schwalm S, Pfeilschifter J, et al. Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks[J]. Frontiers in pharmacology, 2016, 7: 167.
[4] Sun H, Hu B, Wu C, et al. Targeting the SPHK1/S1P/S1PR2 axis ameliorates GH‐secreted pituitary adenoma progression[J]. European Journal of Clinical Investigation, 2024, 54(3): e14117.
[5] Pitman M R, Lewis A C, Davies L T, et al. The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism[J]. Scientific reports, 2022, 12(1): 454.
[6] Xu Q, Chen J, Zhu Y, et al. JTE-013 alleviates inflammatory injury and endothelial dysfunction induced by sepsis in vivo and in vitro[J]. Journal of Surgical Research, 2021, 265: 323-332.
[7] Zhou J, Song Y, Wang X, et al. JTE-013 alleviates pulmonary fibrosis by affecting the RhoA/YAP pathway and mitochondrial fusion/fission[J]. Pharmaceuticals, 2023, 16(10): 1444.
[8] Wang Y, Aoki H, Yang J, et al. The role of sphingosine 1‐phosphate receptor 2 in bile‐acid–induced cholangiocyte proliferation and cholestasis‐induced liver injury in mice[J]. Hepatology, 2017, 65(6): 2005-2018.
JTE 013是一种强效、口服可用的靶向S1P2拮抗剂，对大鼠S1P2的IC50值为22±9nM[1]。JTE 013通过靶向S1PR2抑制炎性细胞因子和S1P的产生，减少单核细胞趋化，并抑制RANKL诱导的破骨细胞前体粘附和融合[2]。JTE 013已广泛用于调节平滑肌收缩和减轻啮齿动物缺氧诱导的肺动脉高压[3]。
在体外，JTE 013处理72小时以IC50值为41.17μM显著抑制了GH3细胞活力[4]。JTE 013处理3小时以IC50值为16.6±2.8µM显著抑制了MV411细胞中的神经酰胺生成[5]。用10µM的JTE 013处理4小时恢复了脂多糖（LPS）诱导的人肺微血管内皮细胞(HPMECs)活力下降，降低了炎症水平，并消除了LPS对HPMECs中连接蛋白水平的抑制作用[6]。
在体内，隔日腹腔注射JTE 013（8mg/kg）连续5天可减轻博来霉素诱导的肺纤维化，并抑制小鼠肺组织中RHOA/YAP通路蛋白的表达[7]。在胆管结扎小鼠中隔日腹腔注射2mg/kg剂量的JTE 013连续3天，显著降低了血清总胆汁酸水平并缓解了胆汁淤积性肝损伤[8]。
| Cell experiment [1]: | |
Cell lines | Human pulmonary microvascular endothelial cells (HPMECs) |
Preparation Method | HPMECs were cultured at a density of 1×105 cells in endothelial cell medium supplemented with 10% fetal bovine serum (FBS) and 2% endothelial cell growth supplements (ECGS). LPS was used to establish a cell injury model induced by sepsis. After cell confluence reached 90%, the cells were divided into the control group, LPS group, and LPS+JTE 013 group. Cells in the LPS group were treated with LPS (1µg/ml) for 4 hours. Cells in the LPS+JTE 013 group were pretreated with LPS (1µg/ml) and then treated with JTE 013 (10µM) for 4 hours. Cell viability and inflammatory factor levels were analyzed. |
Reaction Conditions | 10µM; 4h |
Applications | JTE 013 treatment restored the decreased cell viability induced by LPS and decreased levels of TNF-α, IL-1β, and IL-6 in HPMECs. |
| Animal experiment [2]: | |
Animal models | BALB/c nude mice |
Preparation Method | GH3 xenograft model was established in BALB/c nude mice, GH3 cells (2.5×106 cells) mixed with Matrigel were subcutaneously implanted into the abdomen of 6-8 weeks old male mice (JTE 013 group, n=6; control group, n=6). Tumor size was measured every 3 days, and tumor volume was estimated as width2×length×0.5. When the tumor volume approached 100mm3, JTE 013 was administered by gavage once daily at a dose of 2.5mg/kg. At the end of the 28-day experiment, all mice were sacrificed and tumors were removed for analysis. |
Dosage form | 2.5mg/kg/day for 28 days; p.o. |
Applications | JTE 013 treatment resulted in a significant inhibition of tumor growth and led to a reduction in body weight in GH3 xenograft mice. |
References: | |
| Cas No. | 383150-41-2 | SDF | |
| 化学名 | N-(3,5-dichloropyridin-4-yl)-2-(1,3-dimethyl-4-propyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide | ||
| Canonical SMILES | ClC1=C(C(Cl)=CN=C1)NC(NNC2=CC(CCC)=C3C(N(C)N=C3C)=N2)=O | ||
| 分子式 | C17H19N7OCl2 | 分子量 | 408.29 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4492 mL | 12.2462 mL | 24.4924 mL |
| 5 mM | 489.8 μL | 2.4492 mL | 4.8985 mL |
| 10 mM | 244.9 μL | 1.2246 mL | 2.4492 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet